Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 1/20 | 0.38 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.38 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.38 |
| ▸ | DHFR | P00374 | 2/20 | 0.37 |
| ▸ | HMGCR | P04035 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | PLAU | P00749 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12044436 | 0.85 | CRHR1 (0.43) | QPCTQPCTLCRHR1DHFRGABRG2 | |
| SCHEMBL13920403 | 0.81 | PDE4A (0.39) | QPCTQPCTLCRHR1GABRG2GABRB3 | |
| SCHEMBL23499218 | 0.81 | QPCT (0.36) | QPCTQPCTLCRHR1CYP1A2METAP2 | |
| SCHEMBL23519011 | 0.81 | QPCT (0.36) | QPCTQPCTLCRHR1CYP1A2METAP2 | |
| SCHEMBL26977491 | 0.80 | DHFR (0.51) | DHFR | |
| SCHEMBL30135505 | 0.80 | CYP1A2 (0.38) | QPCTQPCTLCRHR1CYP1A2METAP2 | |
| SCHEMBL13920402 | 0.79 | CD274 (0.40) | QPCTQPCTLCRHR1CYP1A2METAP2 | |
| SCHEMBL23518895 | 0.78 | LMNA (0.39) | QPCTQPCTLCRHR1GABRG2GABRB3 | |
| SCHEMBL24890516 | 0.77 | MTNR1A (0.41) | QPCTQPCTLGABRG2GABRB3GABRA2 | |
| SCHEMBL3933803 | 0.77 | KDM4E (0.47) | GABRG2GABRB3GABRA2FAAHCES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008001070-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004302-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | disclosed |
| US-20080004302-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | disclosed |
| US-4818277-A | HERBICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-04-04 | — | — | US | disclosed |
| EP-0035893-B1 | HERBICIDAL BENZENE- AND PYRIDINE-SULFONAMIDE DERIVATIVES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-11-21 | — | — | EP | disclosed |
| EP-0035893-A2 | Herbicidal benzene- and pyridine-sulfonamide derivatives | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004302-A1 | Novel Compounds | CYP11B2, CYP11B1, CYP46A1 | QPCT 836/4885QPCTL 2600/4885CRHR1 914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.